

# Lung Committee

## Leadership

Chair: ..... Jhanelle E. Gray, MD  
 Vice-Chair: ..... Roy S. Herbst, MD, PhD  
 Executive Officer: ..... Anne Chiang, MD, PhD  
 Statisticians: ..... Mary Redman, PhD  
 ..... Yingqi Zhao, PhD  
 ..... Mia Hsieh, MS  
 ..... Katie Minichiello, MS  
 ..... Jieling Miao, MS  
 ..... James Moon, MS

## Scientific Leadership

Translational Medicine:  
 Biology/Pathology: ..... Philip C. Mack, PhD  
 ..... Fred R. Hirsch, MD, PhD  
 ..... Ignacio I. Wistuba MD  
 Imaging: ..... Chadwick L. Wright MD, PhD  
 ..... Myrna C. Godoy, MD, PhD  
 Radiation Oncology: ..... Henry Park, MD  
 Surgery: ..... Wayne L. Hofstetter, MD  
 Subcommittee Chairs:  
 Early Stage Disease: ..... Wayne L. Hofstetter, MD  
 ..... Raymond Osarogiagbon, MD  
 Locally Advanced Disease: ..... Shirish Gadgeel, MD (Early Therapeutics)  
 Metastatic Disease: ..... Ross Camidge, MD  
 ..... Karen Reckamp, MD  
 Community Engagement: ..... Paul J. Hesketh, MD  
 ..... Suzanne Cole, MD

## Designates

Cancer Control Liaison: ..... Gary E. Goodman, MD  
 DEI Champion: ..... Lucy Gansauer, MSN, RN, OCN, CCRP  
 Veterans Affairs: ..... Chao H. Huang, MD  
 ..... Cheryl M. Czerlanis, MD  
 Data Coordinators: ..... Amy Johnson, CCRP  
 ..... Kevin Moralda, BS  
 ..... Larry Kaye  
 ..... Louise Highleyman, BA  
 ..... Pasarlai Ahmadzai, MD, MPH  
 Clinical Research Project Manager: ..... TBD  
 Oncology Research Professionals:  
 CRA: ..... TBD  
 Nurse: ..... Rosalie Zablocki, RN  
 Patient Advocate: ..... Judy Johnson, MBA  
 Pharmaceutical Science: ..... Joyce Lee, PharmD  
 ..... Kimberly McConnell, PharmD

Protocol Project Managers: ..... Justine Trevino  
 ..... Jennifer Beeler (Lung-MAP)  
 Clinical Trials Program Manager: ..... Laura Gildner, MS

## Time/Location

Saturday, October 14, 2023 9:15 a.m. - 12:15 p.m.  
 Room: Regency C (Ballroom Level, West Tower)

## Agenda

9:15 - 9:20 am General Update: Jhanelle E. Gray, MD  
 9:20 - 9:25 am Patient Advocate Update: Judy Johnson, MBA  
 9:25 - 9:30 am Thoracic Surgery Session: Eric Toloza, MD, PhD  
 9:30 - 9:35 am Thoracic Radiation Session: Megan Daly, MD  
 9:35 - 9:40 am Translational Medicine Session: Philip C. Mack, PhD  
 9:40 - 9:45 am Community Engagement Core: Paul J. Hesketh, MD  
 9:45 - 9:50 am DEI Session: Lucy Gansauer, MSN, RN  
 9:55 - 10:05 am Speaker: AEGEAN Trial - John V. Heymach, MD, PhD  
 Chair, Thoracic/Head & Neck Medical Oncology, The University of Texas  
 MD Anderson Cancer Center  
 10:05 - 10:30 am Debate Panel: Is Neoadjuvant Chemo-IO better than  
 Adjuvant Chemo-IO?  
 Pro-Neoadjuvant Chemo-IO: speaker TBA  
 Pro-Adjuvant Chemo-IO: Barry Gibney, DO  
 Moderator: Jhanelle E. Gray, MD  
 10:30 - 11:30 am Thoracic Medical Oncology Session: Jhanelle Gray, MD  
S2302, "Project Pragmatica-Lung Trial." Dr. Karen Reckamp\*\*. Activated:  
 3/6/23; Accrual: 112.  
LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies  
 and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer  
 (Lung- Map Screening Study)." Drs. Karen Reckamp and David Gandara  
 (SWOG). Activated: 1/28/19; Accrual: 3154.  
S1900E, "A Phase II Study of Sotorasib (AMG 510) in Participants with  
 Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-  
 Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-  
 STUDY)." Dr. Karen Reckamp (SWOG). Dr. Suki Padda and Dr. David Gerber  
 (ECOG). Activated: 4/2/21; Accrual:98.

# Lung Committee

**S1900G**, "A Randomized Phase II Study of Capmatinib plus Osimertinib (Tagrisso) with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung- MAP Sub-Study)". Dr. Sarah Goldberg and Dr. Ross Camidge (SWOG). Activated: 4/3/23; Accrual Goal: 66 (60 eligible); Accrual: 5.

**EA5182**, "Randomized Phase III Study of Combination Osimertinib and Bevacizumab Versus Osimertinib Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant NSCLC". Dr. Sarah Goldberg (SWOG). Activated: 10/22/20; Accrual: 125.

**S1827**, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small- Cell Lung Cancer (MAVERICK)." Dr. Chad Rusthoven (SWOG). Activated: 1/10/20; Accrual:171.

**S1933**, "A Pilot Trial of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Dr. Raid Aljumaily (SWOG). Activated: 6/15/20; Accrual: 30.

**S1914**, "A Randomized Phase III trial of Induction/Consolidation Atezolizumab +SBRT versus SBRT Alone in High risk, Early Stage NSCLC." Dr. Megan Daly (SWOG). Activated: 3/25/20; Accrual: 247.

**EA5163/S1709**, "INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post-progression in Advanced Nonsquamous Non- Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Anne Chiang (SWOG). Activated: 2/28/19; Accrual: 555 total; 73.

11:05 - 11:30 am Open Discussion

## Active Studies

**LUNGMAP**, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)." Drs. Borghaei, Reckamp, Gandara, et al. Activation: 1/28/19.

**S1900E**, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Padda and Gerber. Activation: 4/2/21.

**S1900G**, "A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Goldberg and Camidge. Activation: 4/3/23.

**S1701**, "A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma." Drs. Tsao and Koczywas. Activation: 8/9/18.

**S1827**, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activation: 1/10/20.

**S1914**, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activation: 3/25/20.

**S1933**, "A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Drs. Aljumaily, Mitin, and Wozniak. Activation: 6/15/20.

**S2302**, "PROJECT PRAGMATICA: A Prospective Randomized Study of Ramucirumab (NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-small Cell Lung Cancer in Standard Practice." Drs. Reckamp and Dragnev. Activation: 3/6/23.

**CTS/EA5163/S1709**, "INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Chiang. Activation: 2/28/19.

**CTS/A081801**, "Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)." Dr. Gray. Activation: 6/3/20.

**CTS/A151216**, "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHE-MIST)." Dr. Gandara. Activation: 8/18/14.

**CTS/E4512**, "A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein." Dr. Li. Activation: 8/18/14.

# Lung Committee

**CTSU/EA5181**, “Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC.” Dr. Harkenrider. Activation: 4/9/20.

**CTSU/EA5182**, “Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC).” Dr. Goldberg. Activated:10/22/20.

**CTSU/EA5191**, “A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC.” Dr. Massarelli. Activated: 5/22/20.

**CTSU/NRG-LU002**, “Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial.” Dr. Gomez. Activation: 4/7/17; Temporary closure: 11/12/21.

**CTSU/NRG-LU005**, “Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab.” Dr. Hsu. Activation: 5/28/19; Closed to US and Canadian sites 6/23/22.

**CTSU/NRG-LU007**, “Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial.” Dr. Park. Activated: 8/17/20.

## Closed Studies

**CTSU/NRG-CC003**, “Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer.” Dr. Gaspar. Activation: 12/7/15; Temporary closure: 5/28/20; Reactivation: 7/27/20; Permanent closure: 6/21/22.

**S1800A**, “A Phase II Randomized Study of Ramucirumab Plus Pembrolizumab (MK-3475) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study).” Drs. Reckamp and Dragnev. Activation: 5/17/19. Permanently closed: 10/20/20.

**S1800D**, “A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study).” Drs. Wrangle and Husain. Activation: 2/15/22. Permanently closed: 3/10/23.

**S1900A**, “A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study).” Drs. Riess and Wheatley-Price. Activation: 1/28/19. Permanently closed: 2/2/21.

**S1900B**, “A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study).” Drs. Elamin and Gray. Activation: 2/10/20. Permanently closed: 5/1/21.

**S1900C**, “A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study).” Drs. Skoulidis and Suga. Activation: 1/16/20. Permanently closed: 12/18/20.

**S1900F**, “A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study).” Drs. Gray and Elamin. Activation: 7/25/22. Permanently closed: 6/27/23.

**S1929**, “Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SFLN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC).” Drs. Karim, Reckamp, Gay, et al. Activation: 6/15/20; Step 1 Registration Permanently Closed 8/15/22; Step 2 Permanently Closed 10/15/22.

**S1934**, “NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer.” Drs. Osarogiagbon, Huang, Decker, et al. Activation: 9/9/21; Temporary closure: 11/5/21; Reactivation: 2/15/22; Permanently closed 3/1/23.

## NCI-Approved Concepts

**S1900J**, “A Phase II Study of Amivantamab-vmjw in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).” Drs. Rolfo and Gadgeel.

**S1900K**, “A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).” Drs. Paik and Le.

# Lung Committee

**S2313**, "Neoadjuvant chemo-durvalumab for clinical stage I, 2-3.9cm, non-small cell lung cancer: a randomized controlled trial." Drs. Gibney and Wrangle.

**S2404**, "Accelerating Drug Efficacy Evaluation thru Growth Rate and Overall Survival Correlations" Dr. Lawrence Schwartz and Dr. Karen Reckamp.

**S2409**, "PRISM: A Multicohort PReclision SCLC Subtype Maintenance Phase II Trial of Durvalumab Ver-sus Biomarker-Directed Novel Agents in Combination with Durvalumab in Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Chiang and Chiappori.

**S2410**, "A randomized phase II study of a PDL1 inhibitor and iadademstat (ORY-1001) versus investigator's choice of standard of care for second line treatment of extensive stage small cell lung cancer (SCLC)." Drs. Santana-Davila and Puri.

## Concepts in Development

**S1800E**, "A Randomized Phase II Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Waqar and Li.

**S1900L**, "A Randomized Phase II Study of Pembrolizumab and Ramucirumab with or without Tusamitamab-Ravtansine in CEACAM5 Expressing Previously Treated Stage IV or Recurrent NSCLC (Lung-MAP Sub-Study)." Drs. Judd and Petty.

## Lung Committee

### Accrual from trial opening through 6/30/2023 by Institution and Study

	LUNGMAP	S1701	S1800D	S1827	S1900E	S1900G	S1914	S1929
Ascension Providence Hospitals - Southfield	13	-	-	-	-	-	-	3
Ascension Via Christi Hospitals Wichita	1	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	1	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-
Baptist Mem Hlth Care/Mid South MU-NCORP	35	-	-	2	1	-	6	2
Baylor College of Med/Dan L Duncan CCC	-	-	-	1	-	-	-	-
Boston Medical Center	-	-	-	5	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	11	-	-	-	2	-	-	-
Cancer Research Consortium of West Michigan NCORP	3	-	-	-	-	-	2	-
Cancer Research for the Ozarks NCORP	33	-	3	-	-	-	2	2
Ca Res of Wisconsin and N Mich Consort	25	-	2	-	3	-	2	-
Carle Cancer Center NCORP	2	1	-	1	-	-	6	-
Cedars-Sinai Medical Center	17	-	-	-	1	-	-	-
City of Hope Comprehensive Cancer Center	5	1	-	1	-	-	-	-
Columbia University Minority Underserved NCORP	9	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	27	-	-	3	-	-	-	-
CommonSpirit Health Research Institute	37	-	-	-	-	-	1	1
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	2	-	-	-	-	-	-	2
Essentia Health NCORP	16	-	2	-	-	-	2	-
Fred Hutchinson Cancer Research Center LAPS	4	-	-	-	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	2	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	6	-	-	1	-	-	2	3
Georgia NCI Community Oncology Research Program	58	-	4	2	1	-	6	-
Gulf South Minority Underserved NCORP	21	-	1	1	-	-	2	1
Hawaii Minority Underserved NCORP	25	-	-	1	-	-	-	-
Heartland Cancer Research NCORP	137	-	9	3	5	-	26	19
Henry Ford Hospital	7	-	-	-	-	-	-	1
Houston Methodist Hospital	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	1	-	-	-	-
Kaiser Permanente NCORP	78	-	6	-	8	-	2	-
Lahey Hospital and Medical Center	32	-	-	-	-	-	3	1
Loma Linda University Medical Center	6	-	-	-	-	-	-	-
Loyola University Medical Center	22	-	1	-	-	-	-	2
MAVERIC	59	-	3	3	1	-	-	-
Medical U of South Carolina Minority Underserved	15	-	1	-	1	-	-	-
Mercy Medical Center - Des Moines	8	-	-	-	-	-	-	1
Michigan Cancer Research Consortium NCORP	106	-	4	1	6	-	3	3
Mission Hospital	1	-	-	-	-	-	-	-
Moffitt Cancer Center	14	2	1	1	1	-	-	-
Montana Cancer Consortium NCORP	25	-	-	-	1	-	-	3
Mount Sinai Hospital	-	-	-	-	-	-	9	1
NCORP of the Carolinas (Prisma Health NCORP)	17	-	-	-	1	-	-	-

## Lung Committee

## Accrual from trial opening through 6/30/2023 by Institution and Study

	LUNGMAP	S1701	S1800D	S1827	S1900E	S1900G	S1914	S1929
National Cancer Center-Korea	-	-	-	1	-	-	-	-
Nevada Cancer Research Foundation NCORP	14	-	-	-	-	-	-	1
New Mexico Minority Underserved NCORP	79	-	-	1	2	-	6	5
Northwell Health NCORP	-	-	-	-	-	-	-	-
Northwestern University LAPS	26	1	2	1	-	-	-	4
Oregon Health and Science University	8	-	1	-	-	-	1	-
Pacific Cancer Research Consortium NCORP	15	-	-	-	-	-	-	3
SCL Health Saint Joseph Hospital	1	-	-	-	-	-	1	-
Salem Hospital	3	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	50	-	1	7	1	-	8	8
Sutter Cancer Research Consortium	24	-	-	-	1	-	-	-
The Don and Sybil Harrington Cancer Center	11	-	2	-	-	-	-	-
The J G Brown Cancer Center at University of Louisville	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	35	3	6	1	-	-	10	2
UC Irvine Hlth/Chao Family CCC	23	-	-	1	-	-	1	-
UC San Diego Moores Cancer Center	13	-	-	-	1	-	-	-
UPMC Hillman Cancer Center LAPS	58	-	5	5	6	-	-	3
USC Norris Comprehensive Cancer Center LAPS	-	-	-	3	-	-	5	-
University of Arkansas for Medical Sciences	11	-	1	-	-	-	7	-
U of Cincinnati CC-UC Med Ctr	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	11	-	-	3	-	-	3	2
U of Kansas CC-MCA Rural MU-NCORP	89	-	1	1	1	-	-	-
University of Kentucky/Markey Cancer Center	50	-	-	1	-	-	-	-
University of Michigan Comprehensive Cancer Center	1	-	-	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	32	-	-	1	-	-	1	2
University of Rochester LAPS	63	-	2	-	6	-	3	-
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	-	1
University of Texas MD Anderson Cancer Center LAPS	3	6	-	-	-	-	-	4
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	3	-	-	2	1
Upstate Carolina NCORP	38	-	-	-	-	-	1	-
Wayne State Univ-Karmanos Ca Inst LAPS	1	-	-	-	-	-	-	-
Western States Cancer Research NCORP	2	-	-	-	-	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	39	-	-	1	-	-	8	-
Yale University - Yale Cancer Center LAPS	23	-	-	3	3	-	4	-
ALLIANCE	750	3	15	15	17	1	25	9
CCTG	-	-	-	19	-	-	-	-
ECOG-ACRIN	340	3	5	7	18	-	18	10
NRG	399	1	4	52	7	1	44	6
<b>Total</b>	<b>3,092</b>	<b>21</b>	<b>82</b>	<b>154</b>	<b>95</b>	<b>2</b>	<b>222</b>	<b>106</b>

## Lung Committee

### Accrual from trial opening through 6/30/2023 by Institution and Study

	S1933	S2302	A081801	A082002	A151216	A171901	E4512	EA5163
Ascension Providence Hospitals - Southfield	-	-	-	-	14	-	1	2
Ascension Via Christi Hospitals Wichita	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	1	-	1	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	7	-	2	-
Baptist Mem Hlth Care/Mid South MU-NCORP	-	1	3	-	24	-	-	1
Baylor College of Med/Dan L Duncan CCC	-	-	-	-	-	-	-	-
Boston Medical Center	-	-	-	-	3	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	9	-	53	-	-	16
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	1	-	-	-
Cancer Research for the Ozarks NCORP	3	-	-	-	1	-	-	-
Ca Res of Wisconsin and N Mich Consort	-	-	-	-	-	-	-	-
Carle Cancer Center NCORP	-	1	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	4	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	5	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	2	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-	3	-	-	-
Dayton NCI Community Oncology Research Program	-	-	1	-	8	-	-	-
Essentia Health NCORP	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	15	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	1	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	9	-	-	1
Gulf South Minority Underserved NCORP	-	3	1	-	1	-	-	3
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	2	11	-	-	-	-	-	-
Henry Ford Hospital	-	-	2	-	29	-	-	-
Houston Methodist Hospital	-	-	-	-	8	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	-	3	3	-	201	-	3	8
Lahey Hospital and Medical Center	2	5	-	-	30	-	-	2
Loma Linda University Medical Center	-	-	-	-	9	-	-	-
Loyola University Medical Center	-	1	-	-	22	-	-	1
MAVERIC	-	-	10	-	31	-	-	3
Medical U of South Carolina Minority Underserved	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	3	-	-	-	-	-	-
Mission Hospital	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	14	-	83	-	1	-
Montana Cancer Consortium NCORP	1	-	-	-	-	-	-	-
Mount Sinai Hospital	-	1	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	1	-	-	-

## Lung Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1933	S2302	A081801	A082002	A151216	A171901	E4512	EA5163
National Cancer Center-Korea	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	1	-	-
New Mexico Minority Underserved NCORP	1	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	1	-	3	-	-	-
Northwestern University LAPS	-	3	-	-	-	-	-	-
Oregon Health and Science University	-	-	7	-	23	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-	4	-	-	-
SCL Health Saint Joseph Hospital	-	-	1	-	3	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	1	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	1	11	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-
The J G Brown Cancer Center at University of Louisville	-	-	-	-	5	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	1	-	2	42	-	1	6
UC Irvine Hlth/Chao Family CCC	-	-	-	-	15	-	1	-
UC San Diego Moores Cancer Center	-	-	-	-	5	-	-	-
UPMC Hillman Cancer Center LAPS	2	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	12	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	2	-	-	1
U of Cincinnati CC-UC Med Ctr	-	-	-	-	22	-	1	1
University of Colorado Cancer Center LAPS	-	-	2	-	58	-	2	-
U of Kansas CC-MCA Rural MU-NCORP	-	-	1	-	30	-	-	6
University of Kentucky/Markey Cancer Center	-	-	-	-	5	-	-	-
University of Michigan Comprehensive Cancer Center	-	-	-	-	62	-	-	-
University of Mississippi Medical Center	-	-	-	-	26	-	-	-
University of Oklahoma Health Sciences Center LAPS	11	1	-	-	-	-	-	-
University of Rochester LAPS	-	-	-	-	-	-	-	2
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	-	2
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	2	-	1	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	1
Upstate Carolina NCORP	-	-	-	-	-	-	-	-
Wayne State Univ-Karmanos Ca Inst LAPS	-	-	-	-	1	-	-	-
Western States Cancer Research NCORP	-	-	-	-	1	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	2	-	-	-
Wisconsin NCI Community Oncology Research Program	-	1	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	1	5	-	54	-	4	12
ALLIANCE	5	5	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	5	-	-	-	-	-	-
NRG	1	3	-	-	-	-	-	-
<b>Total</b>	<b>29</b>	<b>54</b>	<b>61</b>	<b>3</b>	<b>949</b>	<b>1</b>	<b>17</b>	<b>68</b>



## Lung Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	EA5181	EA5182	EA5191	NRGCC003	NRGLU002	NRGLU005	NRGLU006	R1308
Ascension Providence Hospitals - Southfield	3	-	1	-	-	-	-	-
Ascension Via Christi Hospitals Wichita	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	2	-	-
Banner University Medical Center - Tucson	10	-	-	-	-	1	-	-
Baptist Mem Hlth Care/Mid South MU-NCORP	1	1	-	-	1	4	-	-
Baylor College of Med/Dan L Duncan CCC	-	-	-	-	-	-	2	-
Boston Medical Center	1	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	18	1	1	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-
Ca Res of Wisconsin and N Mich Consort	-	-	-	-	-	-	-	-
Carle Cancer Center NCORP	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	1	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Essentia Health NCORP	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	4	-	-	-	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	1	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	-	3	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	1
Loyola University Medical Center	2	-	-	-	-	-	-	-
MAVERIC	-	-	2	-	-	-	-	-
Medical U of South Carolina Minority Underserved	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-
Mission Hospital	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-
Mount Sinai Hospital	1	1	-	-	-	1	-	-

# Lung Committee

## Accrual from trial opening through 6/30/2023 by Institution and Study

	EA5181	EA5182	EA5191	NRGCC003	NRGLU002	NRGLU005	NRGLU006	R1308
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	-
National Cancer Center-Korea	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	-
Northwestern University LAPS	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-
SCL Health Saint Joseph Hospital	-	-	-	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	3	-	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-
The J G Brown Cancer Center at University of Louisville	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	1	-	-	-	-	-	-
UC Irvine Hlth/Chao Family CCC	-	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	2	-	-	-	-	1	-	-
U of Cincinnati CC-UC Med Ctr	-	1	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	1	-	-	1	-	-
U of Kansas CC-MCA Rural MU-NCORP	-	-	3	-	-	2	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center	-	-	-	-	-	-	-	-
University of Mississippi Medical Center	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	1	-	-	-	-	-	-	-
University of Rochester LAPS	17	-	-	4	-	1	-	-
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-
Upstate Carolina NCORP	-	-	-	-	-	-	-	-
Wayne State Univ-Karmanos Ca Inst LAPS	-	-	-	-	1	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-
<b>Total</b>	<b>64</b>	<b>8</b>	<b>8</b>	<b>5</b>	<b>2</b>	<b>13</b>	<b>2</b>	<b>1</b>